Benzoyl Peroxide

Evidence Level: L5

Predicted Indications: 4

Benzoyl Peroxide

Pharmacist Assessment Report

Benzoyl Peroxide: From Acne and Dermatitis to Vulvar Inverted Follicular Keratosis

One-Sentence Summary

Benzoyl peroxide is a topical agent originally used for acne and several inflammatory skin conditions, including dermatitis and seborrheic keratosis. The TxGNN model predicts it may be effective for vulvar inverted follicular keratosis, but no clinical trials and no publications currently support this prediction, so it rests on model output alone.

Quick Overview

Item	Content
Original Indication	Acne (the data compiled for this report contain no approved-indication text for the Canadian licences; acne is taken from the original indication list)
Predicted New Indication	Vulvar inverted follicular keratosis
TxGNN Prediction Score	0.9992
Evidence Level	L5
Canada Market Status	Marketed (marketed DINs on record: at least 20)
Number of DINs	at least 20
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available. Based on known information, benzoyl peroxide is a long-established topical agent with antibacterial, comedolytic and anti-inflammatory activity in acne, and it may be mechanistically applicable to follicular and keratinocyte-related skin conditions.

The predicted condition, inverted follicular keratosis, is a benign lesion related to seborrheic keratosis, which is one of benzoyl peroxide’s listed original indications. This suggests a plausible indirect link through keratinocyte and follicular pathology.

However, there is no vulvar-specific evidence. Benzoyl peroxide is also a known skin irritant, and the risk of irritation on vulvar and mucosal skin would have to be carefully considered.

Other Predicted Indications (for reference)

Rank	Predicted Indication	TxGNN Score	Evidence Level	Comment
2	2-Hydroxyethyl methacrylate sensitization	0.9943	L5	Benzoyl peroxide is itself a contact sensitizer and an acrylate polymerization initiator, so it could worsen rather than treat this condition.
3	Acrodermatitis chronica atrophicans	0.9917	L5	A late Borrelia skin manifestation that needs systemic antibiotics; the rationale for a topical agent is weak.
4	Acne keloid	0.9906	L5	Overlaps with acne pathology; only indirect literature is available. Possible adjunctive use at most.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

No literature is available for the top predicted indication. For the fourth-ranked prediction (acne keloid), one indirectly related paper was found:

PMID	Year	Type	Journal	Key Findings
39090034	2024	Review (retrospective chart review)	Dermatology Online Journal	Review of 77 Black paediatric patients with acne vulgaris, describing presentation, scarring/keloid formation and treatment patterns. It is not specific to acne keloidalis and gives no efficacy data.

Canada Market Information

Twenty single-ingredient licences are currently valid, and none are cancelled. The data compiled for this report do not include dosage form or approved-indication text, so those fields are left blank. Five main authorizations:

DIN	Product Name	Dosage Form	Approved Indication
02162113	BENZAGEL 5 GEL	Not listed	Not listed
02162121	BENZAGEL 5 WASH	Not listed	Not listed
02236396	CLEAN & CLEAR PERSA-GEL 5	Not listed	Not listed
02504634	PANOXYL ACNE WASH	Not listed	Not listed
02440512	STUBBORN ACNE SPOT GEL	Not listed	Not listed

Most of the other products are acne cleansers, treatments and kits (e.g., several PROACTIV products).

Safety Considerations

Package insert warnings, contraindications and drug interaction data were not available. Please refer to the package insert for safety information.

Disease associations from the TxGNN knowledge graph (not taken from label text) list the following as contraindicated conditions. They should be verified against the official labelling:

Skin and photosensitivity: photosensitivity disease, photoparoxysmal response, exfoliative dermatitis, dermatitis, skin atrophy, telangiectasis, hereditary hemorrhagic telangiectasia
Infections and warts: anogenital human papillomavirus infection, common wart
Gastrointestinal: Crohn disease, Crohn’s colitis, ulcerative colitis, inflammatory bowel disease, Clostridium difficile colitis, perinatal necrotizing enterocolitis
Metabolic and endocrine: diabetes mellitus, diabetic ketoacidosis, adrenocortical insufficiency, Addison disease
Renal and vascular: kidney disease, pyoureter, capillary disease, peripheral vascular disease, peripheral arterial disease, intermittent vascular claudication

Anogenital warts and a history of dermatitis appear in this list and are particularly relevant to any vulvar use.

Conclusion and Next Steps

Decision: Hold

Rationale: The prediction score is very high (0.9992), but it is supported by no trials or literature (Evidence Level L5). The mechanism of action and safety labelling are also missing, and there is a real risk of irritation on vulvar skin.

To proceed, the following is needed:

Safety information from the Health Canada package inserts (warnings, contraindications), which is currently a blocking gap
Detailed mechanism of action data (MOA)
A literature search for inverted follicular keratosis and seborrheic keratosis, with case reports of topical treatment
Assessment of mucosal and vulvar tolerability, including irritation and sensitization risk
Confirmation of the dosage forms and approved indications for the Canadian products
Expert dermatological and gynaecological review of the clinical relevance before any study is designed
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.